Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024

Go back to Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2024

Barclays Downgrades Illumina (ILMN) to Underweight

February 10, 2025 6:13 AM EST

Barclays analyst Luke Sergott downgraded Illumina (NASDAQ: ILMN) from Equalweight to Underweight with a price target of $100.00 (from $130.00).

The analyst comments "Overall, we view ILMN as a great business with a technological edge that has matured along with the market it created. We think that it is a normal Tools business not unlike other mature genomics / proteomics markets like PCR and mass spec. These are solid MSD topline growers with an oligopoly... More

TD Cowen Downgrades Illumina (ILMN) to Hold

February 7, 2025 7:38 AM EST

TD Cowen analyst Dan Brennan downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $140.00 (from $177.00).

The analyst comments "We downgrade to Hold post 4Q due to sev. factors: 1) accelerating high throughput (HTP) NGS consumable growth (via... More